100% Quality Guarantee
PhD-Level Technical Support
Key Features

Brodalumab Biosimilar (IL17RA) Antibody (HDBS0038)

SKU HDBS0038
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein IL-17RA
Reactivity Human
Host Species Human
Isotype IgG2
€431

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Brodalumab Biosimilar (IL17RA) Antibody (HDBS0038)

Based on the information provided in the URL, I have created a product description for the IL17RA/Brodalumab Biosimilar MAB (HDBS0038):The IL17RA/Brodalumab Biosimilar MAB (HDBS0038) is a monoclonal antibody designed for research involving IL17RA, a cell surface receptor known for its role in inflammation and immune regulation. This biosimilar antibody, developed as a potential alternative to brodalumab, is highly specific and reactive with human samples, making it a valuable tool for studying the IL17RA pathway in various cell types.IL17RA is a key player in the immune response, particularly in autoimmune diseases and chronic inflammatory conditions. By targeting IL17RA, researchers can explore potential therapeutic strategies for treating conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease.

The Anti-IL17RA/Brodalumab Biosimilar MAB (HDBS0038) enables precise detection and analysis of IL17RA in biological samples, providing insights that can drive drug development and personalized medicine approaches. Overall, this biosimilar monoclonal antibody offers a reliable and validated solution for studying the IL17RA pathway and its involvement in immune-mediated disorders, paving the way for innovative research and therapeutic advancements in immunology and inflammatory disease management.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose